Research Associate / Research Fellow in Molecular Imaging Science (in vitro and in vivo biology)
The role is to perform radiopharmaceutics research and provide specialist expertise as a biologist/physicist within a multidisciplinary EPSRC-funded Programme: Next Generation Radiochemistry for Molecular Imaging with Radionuclides (MITHRAS), based at King’s College London, Imperial College and the University of Southampton. The team will include specialists in radionuclide production, nanodrug and cell therapy researchers, organic and inorganic radiochemists, and molecular imaging biologists, and will be embedded within a wider collaborative network comprising the Imaging Chemistry and Biology Department and the School of Biomedical Engineering and Imaging Sciences at King’s, and a network of major internal and external collaborations with other major London universities and hospitals. The aim of the programme is to develop new chemistry for fast, accessible synthesis of radiopharmaceuticals, and translate this into clinically translatable products for imaging and radionuclide therapy.
For this post we are looking for someone with a range of biomolecule and cell labelling, radiochemistry, and preclinical biological evaluation and in vivo molecular imaging skills. This role will encompass varied responsibilities, including work on a wide range of collaborative projects. The Molecular Imaging Scientist will perform preclinical research in radiopharmaceutics, especially biological validation of radiolabelled biomolecules in both cancer and cardiovascular-related related applications. This will include preparation and labelling of small molecules, biomolecules, nanoparticles etc., and in vitro, ex vivo and in vivo biological studies, including preclinical (mainly PET, SPECT, CT, but also potentially optical and MR) imaging. Their primary objective will be to work collaboratively with research groups both across the MITHRAS programme and elsewhere, to drive the development and translation of radionuclide-based molecular imaging and therapy agents.